Last reviewed · How we verify
AK156
AK156 is a humanized monoclonal antibody that blocks the PD-1 checkpoint pathway to enhance anti-tumor immune responses.
AK156 is a humanized monoclonal antibody that blocks the PD-1 checkpoint pathway to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation).
At a glance
| Generic name | AK156 |
|---|---|
| Sponsor | Asahi Kasei Pharma Corporation |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
AK156 binds to programmed death receptor 1 (PD-1) on T cells, preventing interaction with its ligands (PD-L1 and PD-L2) expressed on tumor cells and immune cells. This blockade releases the brake on T cell-mediated immunity, allowing enhanced proliferation, activation, and cytotoxic function against cancer cells. The mechanism is similar to other PD-1 inhibitors used in immuno-oncology.
Approved indications
- Non-small cell lung cancer
- Other solid tumors (under investigation)
Common side effects
- Fatigue
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Infusion reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |